CRISPR Screening Reveals How Genetic Variants Drive Neurodegenerative Risk

November 19, 2026 - 06:35
 0  0
CRISPR Screening Reveals How Genetic Variants Drive Neurodegenerative Risk

Research has started to bridge the gap between identifying genetic changes that can increase the risk of brain conditions, such as Alzheimer’s disease (AD), and understanding how they might impact specific cell functions. Researchers at the Wellcome Sanger Institute, Open Targets, and collaborators, differentiated human induced pluripotent stem cells (iPSCs) derived from different donors into microglia-like (iMGL) cells, and showed how genetic variants impact cell behavior, and more specifically, how they can lead to differences in the ability of brain immune cells to move and clear away biological debris.

Through their research the team also used CRISPR gene editing to show how one gene’s effect depends on its cellular context. They found that the impact of a genetic mutation can be completely opposite depending on the precise cell type and its environment, which is highly important for designing future targeted therapies. The study provides an indication of how to connect genetic risk variants with their downstream effects, as a next step in understanding how genes impact health conditions.

Andrew Bassett, PhD, at the Wellcome Sanger Institute and Open Targets, said, “While genetic studies have identified around a hundred genomic regions linked to Alzheimer’s, pinpointing the exact genes involved and how they alter cell behavior has been more of a challenge. By growing brain immune cells from stem cells across hundreds of donors, we’ve built a framework that directly connects genetic risk to real cell functions, such as how effectively these cells clear debris in the brain. We also discovered that the impact of a genetic variant can change depending on its cellular environment, in some cases having the opposite effect. This suggests that we can’t just look at the impact of these genetic changes in isolation or in one cell. Instead, knowing the exact cell context is essential to understanding how these genetic changes impact health.”

Bassett is co-senior author of the researchers’ published paper in Nature Genetics, titled “Integrated QTL mapping and CRISPR screening in pooled iPSC-derived microglia reveals genetic drivers of neurodegenerative risk.” In their report the authors concluded, “By contextualizing variant effects within iMGLs in different inflammatory states, we provide a comprehensive framework for interpreting the function of risk loci in neurodegenerative disorders.”

Genome wide association studies (GWAS) scan genomes and highlight which differences, known as genetic variants, are more often found in patients with specific health conditions. However, while they can signpost regions of the genome they do not explain how those regions alter gene and cell function. “Genome-wide association studies (GWAS) have identified thousands of variants linked to complex traits and diseases, but translating these into biological insight remains challenging,” the authors wrote. “Most variants are non-coding and probably influence disease by regulating gene expression in specific cell types, states or environments.”

To bridge the gap, the researchers developed a framework to map GWAS data to changes in gene expression and cell behavior. For this, they used 261 human stem cell lines to derive brain cells known as microglia, which are a type of specialized immune cell that move around the brain and remove cellular debris or misfolded proteins. This process,  phagocytosis, is an important part of maintaining healthy neuronal function. As the team pointed out, “Mounting evidence implicates microglia in neurodegeneration, but linking disease-associated genetic variants to target genes and cellular phenotypes is hindered by the inaccessibility of these cells,” they pointed out.

First, the team identified which genetic variants change the levels of different genes in microglia cells. Next, they asked if genetic regions that have been previously linked to Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS) also modulate gene levels. This analysis identified 79 regions. “Expression quantitative trait locus (eQTL) analysis identified 7,121 eQTL-associated genes and 79 colocalizations across four neurodegenerative disease genome-wide association studies, half of which had limited prior evidence of causality,” they stated.

These links alone do not inform of the impact on cell function, so to further understand how these changes in gene expression alter cell behavior, the researchers conducted laboratory tests on the microglia, measuring the cells’ ability to move and undertake phagocytosis. Through these tests and computational modeling, they were able to map 34 genes to changes in cell behavior. This highlighted disease-relevant variants at TREM2 that were linked to changes in phagocytosis.

To understand further how these genes impact behavior of microglia, the team conducted CRISPR screens, knocking out 251 disease-relevant genes. This also allowed them to show that the impact of the gene depends on the cellular context. For example, knocking out TREM2 increases phagocytosis in microglia but decreases it in macrophages, a different type of immune cell. “These results demonstrate that modulation of TREM2 leads to different phenotypic outcomes depending on the cell type, and emphasize the importance of cellular context when interpreting its function in neurodegeneration,” the authors stated.

This research gives a scalable blueprint for studying brain immune cells, which are impossible to safely take samples of in living patients. It could also help find new pathways and drug targets from disease genetic data, giving insight into the cellular mechanisms that are linked to diseases. In their paper the investigators stated, “In summary, this multifaceted approach enabled us to connect genetic variants to effector genes and gene programs, down stream cellular phenotypes and potential disease mechanisms.”

Co-senior author Gosia Trynka, PhD, at the Wellcome Sanger Institute and Science Director at Open Targets, said, “Brain conditions such as Alzheimer’s are incredibly complicated, and understanding how different parts of our genome are linked to these conditions could help us find new ways to identify or treat them. Identifying the associated part of the genome is the first step but it leaves a large translational gap, and our new research has found a way to bridge the gap between association and understanding the impact on the cell function. Connecting this allows us to start to build a full biological picture of disease and will help design future research to accelerate drug discovery.”

Co-first author Marta Perez-Alcantara, PhD, previously at the Wellcome Sanger Institute and Open Targets, further commented, “This ambitious study showcases the potential of iPSC-derived cells for genetic analysis, linking genetic variation to expression, cellular survival and function, and disease susceptibility. This approach is particularly valuable for difficult-to-access tissues such as the brain, allowing us to investigate genetic effects across multiple donors and stimulation conditions in microglia, which are challenging to obtain in sufficient numbers and under the right stimuli from primary human tissues. This framework has the potential to be extended to other diseases, tissues or cellular phenotypes, enabling research that would otherwise be extremely difficult to undertake.”

The authors added that in a broader context “… our study demonstrates the feasibility and value of integrating genetic association data, single-cell transcriptomics, and pooled functional genomics to investigate genotype–phenotype relationships at scale. This framework is also applicable to other cell types and diseases.”

The post CRISPR Screening Reveals How Genetic Variants Drive Neurodegenerative Risk appeared first on GEN - Genetic Engineering and Biotechnology News.

Apa Reaksi Anda?

Suka Suka 0
Kurang Suka Kurang Suka 0
Setuju Setuju 0
Tidak Setuju Tidak Setuju 0
Bagus  Bagus 0
Berguna Berguna 0
Hebat Hebat 0
Edusehat Platform Edukasi Online Untuk Komunitas Kesehatan Agar Mendapatkan Informasi Dan Pengetahuan Terbaru Tentang Kesehatan Dari Nasional Maupun Internasional. || An online education platform for the health community to obtain the latest information and knowledge about health from both national and international sources.